

Accepted Manuscript

British Journal of General Practice

Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data

Cranfield, Ben; Koo, Minjoung; Abel, Gary; Swann, Ruth; McPhail, Sean; Rubin, Gregory; Lyratzopoulos, Georgios

DOI: <https://doi.org/10.3399/BJGP.2022.0265>

To access the most recent version of this article, please click the DOI URL in the line above.

Received 25 May 2022

Revised 26 August 2022

Accepted 07 September 2022

© 2022 The Author(s). This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License (<http://creativecommons.org/licenses/by/4.0/>). Published by British Journal of General Practice. For editorial process and policies, see: <https://bjgp.org/authors/bjgp-editorial-process-and-policies>

When citing this article please include the DOI provided above.

Author Accepted Manuscript

This is an 'author accepted manuscript': a manuscript that has been accepted for publication in British Journal of General Practice, but which has not yet undergone subediting, typesetting, or correction. Errors discovered and corrected during this process may materially alter the content of this manuscript, and the latest published version (the Version of Record) should be used in preference to any preceding versions

Primary care blood tests before cancer diagnosis: National Cancer Diagnosis Audit data

Authors: Ben M. Cranfield (PhD Student)¹,

Dr Minjoung Monica Koo (Research Associate – ORCID: 0000-0001-9832-9872)¹,

Dr Gary A. Abel (Associate Professor in Medical Statistics – ORCID: 0000-0003-2231-5161)²,

Dr Ruth Swann (Public Health England and Cancer Research UK)^{3,4}

Dr Sean McPhail (Public Health England)³

Prof Greg P. Rubin (Professor of General Practice and Primary Care – ORCID: 0000-0002-4967-0297)⁵,

Prof Georgios Lyratzopoulos (Professor of Cancer Epidemiology – ORCID: 0000-0002-2873-7421)¹.

¹University College London, 1-19 Torrington Place, London, WC1E 6BT, UK

²University of Exeter Medical School, St Luke's Campus, Exeter, EX1 2HZ, UK

³National Disease Registration Service, NHS Digital, Leeds, LS1 4AP, UK

⁴Cancer Research UK, 2 Redman Place, London, E20 1JQ, UK

⁵Population Health Sciences Institute, Newcastle University, Newcastle Upon Tyne, NE1 4LP, UK

Abstract

Background: Blood tests can support the diagnostic process but how often they are used in cancer patients is unclear.

Aim: To explore use of common blood tests before cancer diagnosis in primary care

Design and setting: English National Cancer Diagnosis Audit data on 39,752 cancer patients diagnosed in 2018.

Methods: We assessed common blood test use (full blood count (FBC), urea and electrolytes (U&Es), and liver function tests (LFTs)), related variation by patient and symptom group, and associations with the primary care and the diagnostic intervals (PCI, DI).

Results: At least one common blood test was used in 41% of cancer patients. Among tested patients, FBC was used in 95%, U&Es in 88% and LFTs in 74%). Blood testing was less common in women (adjusted odds ratio (aOR) vs men: 0.92, 95%CI: 0.87-0.98) and non-white patients (0.89, 0.82-0.97 vs white) and more common in older patients (1.12, 1.06-1.18 for 70+ vs 50-69 years). Test use varied greatly by cancer-site, (melanoma: 2%, leukaemia 84%). Fewer patients presenting with alarm symptoms alone were tested (24%) than those with non-alarm symptoms alone (50%). Median PCI and DI were longer in tested than non-tested patients (PCI: 10 vs 0; DI: 49 vs 32 days, respectively, $p < 0.001$ for both), including among tested patients with alarm symptoms (PCI: 4 vs 0; DI: 41 vs 22).

Conclusions: Two-fifths of patients subsequently diagnosed with cancer have primary care blood tests. Given variable test use, research is needed on the clinical context in which blood tests are ordered.

“How this fits in”

Evidence relating to the predictive value of blood tests for cancer diagnosis is growing, yet how often they are used by GPs in pre-diagnosed cancer patients is unclear. In England, two-fifths of patients subsequently diagnosed with cancer in 2018 had at least one full blood count, urea & electrolyte or liver function test. Blood test use was less likely in women, non-white and younger patients and more likely in those presenting with non-specific symptoms, with longer intervals to referral and diagnosis being associated with tested patients. This research highlights potential unmet need for interventions to reduce the risk of overuse (in populations presenting with more-specific symptoms) and underuse (in patients presenting with less-specific symptoms) of blood tests in cancer populations.

Introduction

Half of the UK population will be diagnosed with a form of cancer in their lifetime.(1) Increasing cancer survival requires improvements in both treatment and stage at diagnosis. The latter may be achieved through earlier diagnosis of symptomatic patients.

The majority of patients subsequently diagnosed with cancer first present to a general practitioner with symptoms.(2) Decision-making for managing symptomatic presentations can be guided by the results of tests carried out in primary care. In patients with symptoms of possible cancer, the diagnostic utility of abnormalities in blood test results (e.g. low haemoglobin concentration, microcytosis, high platelet count and raised inflammatory markers) has been increasingly understood in recent years.(3–6)

Use of common blood tests in primary care has increased over time, (7) though how often such tests form part of pre-diagnostic care in cancer patients is unclear. Earlier research on patients with six common cancers (lung, colorectal, oesophagus, stomach, pancreas and ovarian) indicates that between 24% (ovarian cancer) and 55% (stomach cancer) of patients had at least one blood test as part of their primary care management pre-referral. (8) Whether there is potential for greater use of common blood tests in patients subsequently diagnosed with cancer is unclear.

Using common blood tests may represent an appealing diagnostic strategy for the large group of patients presenting with non-specific symptoms not meeting referral criteria for specialist investigations or referrals. Cancer patients presenting with non-specific symptoms often experience prolonged diagnostic intervals and complex care pathways.(9–11)

Using data on patients diagnosed in 2018 with common and rarer cancers in England, we aimed to examine how often patients who are subsequently diagnosed with cancer are investigated by common blood tests in primary care as part of the management of their initial presentation; and explore related variation in blood test use by patient characteristic, positing a priori that variation is likely by age, sex, cancer site and symptoms, and potentially by deprivation and ethnicity.

Methods

Study Design and Participants:

Data were analysed from the National Cancer Diagnosis Audit (NCDA) 2018. The source has been described previously.(12) Briefly, data on the diagnostic process of cancer cases diagnosed during 2018 were collected by participating GPs based on information in the primary care records. Included patients were identified by the English Cancer Registry (National Disease Registration Service). In a previous audit, included patients were representative of the national incident population of cancer patients, and participating practices had comparable characteristics to non-participating practices though they were slightly larger.(12)

The analysis sample included 39,752 non-screen-detected cancer patients aged 15 years or older who first presented in general practice and had complete information on investigation status (Figure 1).

Outcome variable:

The audit questionnaire collected information on whether blood tests were used in primary care prior to referral for suspected cancer, as a series of binary items: "Primary care led investigations that were ordered as part of the diagnostic assessment, and prior to referral, decided by the GP and in response to symptoms complained of, signs elicited, or abnormal test results". We defined common blood tests as a binary variable indicating the use of at least one of: full blood count (FBC), urea and electrolytes (U&E) or liver function tests (LFTs). We focused on these blood tests as they are the ones most commonly ordered, and because abnormalities can arise from a large range of disease processes. This is unlike other, more specialist, blood tests with more specific affinity to diseases of a given body organ or system, some of which, however, were considered in addition (see below).

Other variables:

Exposure variables included: age group (15-29, 30-49, 50-69, 70+ years), gender and diagnosis (denoted as 'sex' hereafter; male and female), ethnicity (white, non-white, and unknown), index of multiple deprivation quintile group (based on income domain), count of pre-existing morbidities (0, 1, 2 and 3+ conditions, and missing), cancer site (a 29-group categorical variable) and presenting symptom group.(12)

Information on presenting symptoms was collected regarding the presence of one or more of 83 pre-specified symptoms in the audit questionnaire. We defined alarm symptoms as those where the 2015 National institute for Health and Care Excellence guidelines recommended urgent or immediate referral or specialist investigation (Supplementary Table 1). Three main groups are defined: patients presenting with alarm symptoms; those with non-alarm symptoms; and those with both alarm and non-alarm symptoms. Additionally, two further groups were considered, one comprising alarm symptoms likely to indicate a medical emergency in whom primary care blood testing is not expected to be used, and a group with missing information on the nature of symptoms.

The length of the primary care interval (PCI) was defined consistent with the Aarhus statement: the time from first symptomatic presentation to first referral to specialist care, as was the diagnostic interval (DI): the time from first symptomatic presentation to diagnosis, and examined by investigation status.(13)

Analysis:

Logistic regression was used to estimate crude and adjusted odds ratios (ORs) of common blood test use by age, sex, ethnicity, morbidity status, deprivation group and symptom category. To explore

whether cancer specific factors may influence blood test use beyond these variables, in a further model, we additionally adjusted for cancer-site. Joint Wald tests were used to assess overall variation by variable category.


We described the median and interquartile range (IQR) of PCI and DI by test status (use/non-use of common blood tests), assessing differences between symptom type groups and cancers using Kruskal-Wallis tests. To account for potential confounding or effect mediation of the observed associations between blood test use and length of the PCI or the DI, we used quantile regression models, adjusting for blood test use, sex, cancer site and symptom category (age was not included due to model non-convergence). To examine potential interactions between blood test use and symptom category, we have further expanded the above model to include such an interaction term. Cases with missing information on the PCI (16%) and DI (12%) were excluded from this analysis. Statistical analysis was conducted in STATA SE V.15 (StataCorp).

Supplementary Analysis:

We calculated the proportion of tested patients who received a specific common blood test or combination of tests (hereafter, we refer to patients who had a common blood test as ‘tested’ patients for brevity) and the distribution of blood tests by cancer-site (Supplementary Table 2 & Table 3, respectively). Furthermore, we assessed interactions between ethnicity and deprivation within the adjusted models and found no evidence for such interactions.

A sensitivity analysis repeated the main analysis but after excluding patients recorded as having no consultations though also recorded as having presented to their GP surgery (n=2048, 5% of the main analysis sample). This group were kept in the main analysis, as a large proportion of them (n=1554, 76%) were diagnosed after being referred via 2WW or routinely by their GP.

Figure 1. Derivation of the analysis sample (n=39752)



*Includes 571 patients with more than one tumour.

Accepted Manuscript – BJGP – BJGP.2022.0265

Results

Study population

Of 39,752 included patients, approximately half were 70+ years old (49%), most were of white ethnicity (87%) and with a slight preponderance of men (55%, Table 1). Of included patients 74% had at least one chronic condition, while 19% had three or more. Patients were most commonly diagnosed with prostate (19%), breast (12%), or lung cancer (11%). Over one-third of cases presented with alarm symptoms alone (35%) and over two-fifths with non-alarm symptoms alone (41%), while less than one in five presented with both alarm and non-alarm symptoms (15%). The median (IQR) PCI was 3 (0-20) days, and the median (IQR) DI was 39 (17-81) days.

Use of common blood tests

A total of 16427/39752 (41%) patients had at least one common blood test in primary care before being diagnosed with cancer; variation in blood test use by exposure variable is described in Table 1.

Considering patient characteristics, blood test use was more frequent in men compared with women (48% vs 34%, respectively, $p < 0.001$) and older patients (ranging from <32% in patients younger than 50 and 46% in those 70 years or older, $p < 0.001$). Blood test use was less frequent in non-white compared with white patients (38% vs 42%, respectively, $p = 0.002$), without a clear pattern of variation by deprivation group. Use of blood tests increased with greater number of morbidities (no morbidities: 36%, 3+ morbidities: 45%, $p < 0.001$). Multivariable analysis provided concordant findings, with the exception of the association with comorbidities which was no longer apparent.

There was very large variation in common blood test use by subsequently diagnosed cancer, ranging from 84%, 76% and 71% in patients diagnosed with leukaemia, myeloma and pancreatic cancer, respectively; to 8%, 4% and 2% for patients with vulval cancer, breast cancer, and melanoma, respectively. Adjusted analyses confirmed similar patterns of variation by cancer site.

Common blood tests were used in primary care before cancer diagnosis in around half of patients presenting with either non-alarm symptoms alone or both alarm and non-alarm symptoms together (50% and 56%), but in less than a quarter (24%) of patients presenting with alarm symptoms alone. In adjusted analysis, variation by presenting symptom group remained, i.e. odds ratios of 2.75 (95% CI: 2.61-2.89) and 3.68 (95% CI: 3.44-3.93) for non-alarm symptoms alone and both alarm and non-alarm symptoms together respectively, compared with patients presenting with alarm symptoms alone. Including adjustment for cancer site attenuated these odd ratios to 1.58 (95% CI: 1.49-1.69) and 2.13 (95% CI: 1.98-2.30).

Diagnostic timeliness by use of common blood tests

The median (inter-quartile range) PCI was longer in patients with a blood test than those without (10 days (1-30) vs. 0 day (0-13), $p = 0.001$). The median diagnostic interval was also longer in those tested than those not tested (49 (26-95) vs 32 (14-70) $p = 0.001$, Table 2).

Use of blood tests was associated with longer intervals across all three presenting symptom categories, though the difference was longest in patients with alarm symptoms (19 days). In adjusted analysis, we observed substantial attenuation of the association between blood test use and the length of the PCI (from 10 days in the observed data to 4 days, Table 2); and even more substantial attenuation of the DI (from 17 days in the observed data to 3 days). Additional analysis indicated that the main source of these changes observed after adjustment was cancer site, i.e. patients who are more likely to have a blood test are also those subsequently diagnosed with cancers associated with

longer intervals. Interaction analysis further indicated that adjustment for cancer site and sex led to variable reductions in the observed differences in PCI between those having and those not having a blood test in patients presenting with alarm (from 4 days in the observed data to 1 day), non-alarm (from 9 days in the observed data to 7 days) or both alarm and non-alarm (from 6 days in the observed data to 4 days) symptoms. A similar pattern of variable shortening of intervals by symptom category was observed for the DI (alarm symptoms: from 19 to 3 days; non-alarm symptoms: from 7 to 5 days; alarm and non-alarm symptoms: 12 to 3 days).

Supplementary analysis: blood test signatures and variation in use by cancer-site.

Among tested patients (n=16,427), 95%, 89% and 76% had FBC, U&Es and LFTs, respectively. Nearly 9 in 10 (87%) of tested patients had at least two of these three blood tests and 72% had all three (appendix 2).

For six cancers (pancreatic, myeloma, liver, colon, stomach and leukaemia) FBCs, U&E's and LFTs were ordered in over half of all cases (Table 3). Biomarker tests were most frequently used in patients diagnosed with prostate (86%) and ovarian cancer (47%) – against an average of 24% among all cancers. Inflammatory marker tests were used in 19% of all patients, and more frequently in those diagnosed with myeloma (49%), pancreatic cancer (42%), Hodgkin lymphoma (37%), liver cancer (37%), carcinoma of unknown primary (36%), leukaemia (33%) and colon cancer (33%). Over half of patients diagnosed with myeloma had serum protein tests (53%), while over one-third had bone profile tests (36%). Approximately a third of patients diagnosed with colon cancer (34%) and over a quarter diagnosed with stomach cancer (28%) had ferritin tests, while 17% of patients diagnosed with pancreatic cancer had amylase tests. Findings from the sensitivity analysis (i.e. excluding patients with 'zero' consultations) was concordant with the main analysis (data not shown).

Table 1: Proportions and crude/adjusted ORs examining variation in common blood test use in primary care among individuals diagnosed with cancer

	Population total (column %)	Received a blood test (row %)	Crude OR (95% CI)*	Adjusted OR* (95% CI) (excluding cancer-site)	Adjusted OR* (95% CI) (including cancer-site)
Total	39752 (100%)	16427 (41%)			
Age group			P<0.001**	P<0.001	P=0.001
15-29 years	553 (1%)	172 (31%)	0.66 (0.55-0.79)	0.85 (0.70-1.04)	0.98 (0.77-1.23)
30-49 years	4009 (10%)	1053 (26%)	0.53 (0.49-0.57)	0.69 (0.63-0.75)	0.99 (0.90-1.10)
50-69 years	15746 (40%)	6293 (40%)	Ref	Ref	Ref
70+ years	19444 (49%)	8909 (46%)	1.26 (1.21-1.32)	1.23 (1.18-1.29)	1.12 (1.06-1.18)
Sex			P<0.001	P<0.001	P=0.009
Male	21854 (55%)	10391 (48%)	Ref	Ref	Ref
Female	17898 (45%)	6036 (34%)	0.55 (0.53-0.58)	0.67 (0.64-0.70)	0.92 (0.87-0.98)
Ethnicity***			P=0.002	P=0.47	P=0.02
White	34421 (87%)	14310 (42%)	Ref	Ref	Ref
Non-white	3400 (9%)	1308 (38%)	0.88 (0.81-0.94)	0.96 (0.89-1.04)	0.89 (0.82-0.97)
Unknown	1931 (5%)	809 (42%)	1.01 (0.92-1.11)	1.04 (0.94-1.15)	1.02 (0.92-1.14)
Index of Multiple Deprivation (IMD)			P=0.22	P=0.10	P=0.11
1-Least deprived	8408 (21%)	3422 (41%)	Ref	Ref	Ref
2	8222 (21%)	3474 (42%)	1.07 (1.00-1.13)	1.08 (1.01-1.15)	1.08 (1.01-1.16)
3	7839 (20%)	3219 (41%)	1.02 (0.96-1.09)	1.04 (0.97-1.11)	1.01 (0.94-1.08)
4	7529 (19%)	3131 (42%)	1.04 (0.98-1.11)	1.07 (1.01-1.15)	1.03 (0.96-1.11)
5-Most deprived	7754 (20%)	3181 (41%)	1.01 (0.95-1.07)	1.04 (0.98-1.12)	0.99 (0.92-1.07)
Cancer****			P<0.001	N/A	P<0.001
Leukaemia	661 (2%)	552 (84%)	7.69 (6.18-9.55)		9.24 (7.41-11.52)
Myeloma	599 (2%)	455 (76%)	4.68 (3.84-5.71)		5.16 (4.22-6.31)
Pancreatic	1165 (3%)	826 (71%)	3.61 (3.13-4.16)		3.52 (3.06-4.07)
Liver	471 (1%)	331 (70%)	3.50 (2.85-4.31)		3.69 (2.99-4.55)
Colon	2991 (8%)	2093 (70%)	3.47 (3.14-3.83)		3.84 (3.46-4.25)
Stomach	727 (2%)	448 (62%)	2.39 (2.03-2.81)		2.43 (2.06-2.87)
Rectal	1261 (3%)	764 (61%)	2.29 (2.02-2.61)		2.86 (2.50-3.28)
CUP	629 (2%)	368 (59%)	2.08 (1.75-2.46)		2.19 (1.84-2.60)
Hodgkin Lymphoma	218 (<1%)	121 (56%)	1.83 (1.38-2.41)		2.27 (1.70-3.04)
Ovarian	874 (2%)	482 (55%)	1.81 (1.56-2.10)		1.90 (1.63-2.21)
Non-Hodgkin Lymphoma	1545 (4%)	852 (55%)	1.82 (1.62-2.05)		2.15 (1.91-2.43)
Kidney	969 (2%)	477 (49%)	1.44 (1.25-1.66)		1.62 (1.41-1.87)
Oesophageal	1074 (3%)	504 (47%)	1.30 (1.13-1.49)		1.38 (1.20-1.59)
Prostate	7499 (19%)	3518 (47%)	1.32 (1.23-1.43)		1.42 (1.31-1.55)
Other	2184 (5%)	1004 (46%)	1.28 (1.16-1.42)		1.51 (1.36-1.68)
Bladder	1112 (3%)	481 (43%)	1.13 (0.99-1.29)		1.33 (1.15-1.52)
Mesothelioma	331 (<1%)	143 (43%)	1.14 (0.91-1.43)		1.04 (0.82-1.31)
Lung	4430 (11%)	1785 (40%)	Ref		Ref
Thyroid	467 (1%)	179 (38%)	0.95 (0.78-1.15)		1.38 (1.11-1.70)
Brain	328 (<1%)	123 (38%)	0.88 (0.70-1.12)		0.96 (0.76-1.23)
Cervical	194 (<1%)	59 (30%)	0.63 (0.46-0.87)		0.74 (0.54-1.03)
Oropharynx	523 (1%)	145 (28%)	0.57 (0.46-0.70)		0.70 (0.57-0.86)
Uterus	1266 (3%)	318 (25%)	0.49 (0.43-0.57)		0.65 (0.56-0.76)
Larynx	297 (<1%)	64 (22%)	0.41 (0.31-0.55)		0.50 (0.37-0.66)
Oral cavity	248 (<1%)	28 (11%)	0.18 (0.12-0.28)		0.26 (0.17-0.39)
Testicular	340 (<1%)	33 (10%)	0.16 (0.11-0.23)		0.19 (0.13-0.28)
Vulval	133 (<1%)	10 (8%)	0.12 (0.06-0.23)		0.17 (0.09-0.33)
Breast	4919 (12%)	209 (4%)	0.07 (0.06-0.08)		0.09 (0.07-0.10)
Melanoma	2297 (6%)	55 (2%)	0.04 (0.03-0.05)		0.05 (0.03-0.06)
Morbidities			P<0.001	P=0.90	P=0.40
0	10145 (26%)	3698 (36%)	Ref	Ref	Ref
1	12370 (31%)	5111 (41%)	1.22 (1.16-1.29)	1.01 (0.94-1.06)	0.94 (0.88-1.01)

	Population total (column %)	Received a blood test (row %)	Crude OR (95% CI)*	Adjusted OR* (95% CI) (excluding cancer-site)	Adjusted OR* (95% CI) (including cancer-site)
2	9144 (23%)	4039 (44%)	1.37 (1.30-1.46)	1.01 (0.95-1.08)	0.97 (0.91-1.04)
3+	7401 (19%)	3318 (45%)	1.41 (1.33-1.50)	1.01 (0.93-1.07)	0.96 (0.89-1.03)
missing	692 (2%)	261 (38%)	N/A	N/A	N/A
Symptom types			P<0.001	P<0.001	P<0.001
Alarm only	13778 (35%)	3341 (24%)	Ref	Ref	Ref
Non-alarm only	16487 (41%)	8223 (50%)	3.12 (2.97-3.28)	2.75 (2.61-2.89)	1.58 (1.49-1.69)
Alarm/non-alarm	5832 (15%)	3262 (56%)	3.97 (3.72-4.23)	3.68 (3.44-3.93)	2.13 (1.98-2.30)
Emergency only	173 (<1%)	62 (36%)	1.70 (1.24-2.34)	1.60 (1.16-2.21)	0.94 (0.66-1.32)
Not known/not applicable	3482 (9%)	1539 (44%)	2.48 (2.30-2.69)	2.01 (1.86-2.18)	1.01 (0.92-1.10)

*After excluding 692 patients with missing information on morbidities, 39060 cases remained for the logistic regression models. **Post estimations using Wald tests explained the significance of the explanatory variables on predicting blood test use. CUP = Cancer of unknown primary; CNS = central nervous system; Ref = reference group. ***The non-white group comprised South East Asian (n=858, 2%), Black (1142, 3%), Chinese (165, <1%) and Other (1235, 3%) patients, of which 38% (n=329), 42% (n=474), 36% (n=60) and 36% (n=445) had common blood tests, respectively. **** Cancer-site is presented in descending order of blood test use.

Table 2. Median and inter-quartile range for the Primary Care Interval and the Diagnostic Interval by blood test use, stratified by symptom type

	All patients (independently of blood test status) (n=37752)	Patients having a common blood test (n=16427)	Patients not having a common blood test (n=23325)	Difference by common blood test use	P value*	**Adjusted difference in interval by common blood test use and symptom group	P value
Primary care interval (PCI)	Median (IQR) days	Median (IQR) days	Median (IQR) days	Median days		Median days (95% CI)	
Overall (n=35962)	3 (0-20)	10 (1-30)	0 (0-13)	10	<0.001	4 (3 – 5)	<0.001
Alarm only (n=18627)	0 (0-8)	4 (0-20.5)	0 (0-1)	4	<0.001	1 (1 – 1)	<0.001
Non-alarm only (n=19813)	8 (0-29)	13 (2-34)	4 (0-23)	9	<0.001	7 (6 – 8)	<0.001
Alarm/non-alarm (n=5363)	2 (0-17)	6 (0-22)	0 (0-8)	6	<0.001	4 (3 – 8)	<0.001
Emergency only (n=145)	0 (0-17)	9 (0-25)	0 (0-5)	9	0.017	9 (2 – 16)	0.01
Not known/not applicable (n=2837)	6 (0-27)	9 (1-34)	3 (0-22)	6	<0.001	6 (4 – 8)	<0.001
Diagnostic Interval (DI)	Median (IQR) days	Median (IQR) days	Median (IQR) days	Median days		Median days	
Overall (n=37883)	39 (17-81)	49 (26-95)	32 (14-70)	17	<0.001	3 (1 – 5)	0.001
Alarm only (n=19190)	28 (14-61)	41 (21-79)	22 (13-51)	19	<0.001	3 (1 – 5)	<0.001
Non-alarm only (n=21478)	46 (23-91)	49 (27-97)	42 (20-85)	7	<0.001	5 (3 – 7)	<0.001
Alarm/non-alarm (n=5708)	35 (16-69)	40 (21-77)	28 (14-59)	12	<0.001	3 (1 – 5)	0.007
Emergency only (n=162)	42 (17-86)	51 (22-100)	37 (11-78)	14	0.57	14 (-11– 40)	0.28
Not known/not applicable (n=2872)	56 (29-107)	62 (31-117)	52 (28-100)	10	0.21	11 (6 – 16)	<0.001

* P value from Kruskal-Wallis test, comparing intervals in tested vs non-tested patient groups ** Median (50th) quantile regression (with 500 Bootstrap replications), adjusted for blood test use, symptom category, sex, cancer-site and interaction between blood test use and symptom category. Further adjusting of the diagnostic interval model for age made little difference to the findings. Adjusting of the primary care interval model for age, IMD and comorbidities was not possible due to lack of convergence).

Table 3: Table showing frequency of blood test use by cancer-site

Common blood tests

Less generic tests / tests with greater affinity to specific disease processes

Cancer	Any one of the 3 common Blood tests		Common blood tests								Cancer Biomarkers***											
	tests	%	FBC	%	U&E	%	LFT	%	Inflammatory Markers	%	Use in Men	%	Use in Women	%	Serum protein	%	Ferritin	%	Bone profile	%	Amylase	%
Leukaemia (n=661)	552	84	543	82	370	56	340	51	216	33	39	6	5	1	46	7	115	17	117	18	9	1
Multiple myeloma (n=599)	455	76	439	73	387	65	345	58	295	49	62	10	29	5	320	53	129	22	217	36	9	2
Pancreas (n=1165)	826	71	790	68	763	65	773	66	488	42	89	8	110	9	45	4	224	19	239	21	194	17
Liver (n=471)	331	70	289	61	273	58	301	64	172	37	32	7	31	7	28	6	88	19	91	19	37	8
Colon (n=2991)	2093	70	2075	69	1751	59	1608	54	980	33	192	6	208	7	76	3	1029	34	450	15	98	3
Stomach (n=727)	448	62	444	61	388	53	371	51	205	28	45	6	23	3	16	2	207	28	121	17	36	5
Rectum (n=1261)	764	61	751	60	677	54	621	49	361	29	94	7	58	5	22	2	325	26	141	11	21	2
Unknown primary (n=629)	368	59	349	55	327	52	317	50	228	36	45	7	61	10	29	5	92	15	110	17	34	5
Ovary (n=874)	482	55	476	54	439	50	393	45	258	30	0	0	408	47	14	2	121	14	128	15	33	4
Non-hodgkin lymphoma (n=1545)	852	55	842	54	727	47	666	43	534	35	83	5	60	4	147	10	230	15	288	19	47	3
Kidney (n=969)	477	49	448	46	432	45	358	37	230	24	112	12	26	3	30	3	125	13	120	12	22	2
Oesophagus (n=1074)	504	47	496	46	456	42	422	39	230	21	36	3	18	2	19	2	190	18	125	12	37	3
Prostate (n=7499)	3518	47	3,025	40	3332	44	2337	31	1002	13	6420	86	1	<1%	160	2	374	5	896	12	36	<1%
Other (n=2184)	1004	46	967	44	845	39	764	35	478	22	121	6	100	5	83	4	240	11	266	12	70	3
Bladder (n=1112)	481	43	441	40	458	41	271	24	137	12	247	22	11	1	13	1	76	7	88	8	7	1
Lung (n=4430)	1785	40	1,720	39	1624	37	1420	32	1020	23	142	3	93	2	121	3	399	9	580	13	46	1
Thyroid (n=467)	179	38	175	37	153	33	124	27	81	17	2	<1%	7	1	4	1	21	4	37	8	0	0
Oropharynx (n=523)	145	28	143	27	127	24	103	20	105	20	6	1	1	<1%	8	2	21	4	32	6	0	0
Uterus (n=1266)	318	25	311	25	261	21	222	18	120	9	0	0	146	12	12	1	106	8	69	5	6	<1%
Breast (n=4919)	209	4	192	4	195	4	159	3	98	2	2	<1%	26	1	15	<1%	42	1	76	2	8	<1%
Melanoma (n=2297)	55	2	53	2	49	2	36	2	25	1	2	<1%	1	1	3	<1%	11	<1%	12	1	0	0
All other Cancers (n=2089)**	581	28	571	27	521	25	463	22	335	16	57	3	38	2	29	1	134	6	164	8	11	1
All Patients (n=39752)	16427	41	15,540	39	14555	37	12414	31	7598	19	7828	20	1461	4	1240	3	4299	11	4367	11	761	2

* The boundaries for green-yellow-red are set at the upper, median and lower values for each blood test. All other values are coloured proportionally.

** Cancer-sites with less than 397 cases (i.e. <1% of study population) were grouped together, including Hodgkin lymphoma, Mesothelioma, Brain, Cervical, Larynx, Oral Cavity, Testicular and vulval cancers.

***Cancer biomarkers are stratified by sex and includes PSA, CEA, CA125, CA19.9, and other (unspecified).

Accepted Manuscript – BJGP – BJGP.2024

Discussion

Summary:

Around two fifths of cancer patients who presented in general practice had a common blood test as part of their diagnostic process. Cancer patients who were female, non-white or younger were less likely to have had a blood test. Use of blood tests was greater among patients presenting with less specific symptoms, though many presenting with alarm symptoms were also tested. Patients who had a blood test experienced longer diagnostic intervals.

Strengths and Limitations:

We used data from a large and nationally representative sample of cancer patients. Our findings are based on individuals diagnosed with cancer in 2018; guidelines were updated in 2015, though mostly regarding symptom-based recommendations, not the use of blood tests. (14)

The temporal relationship of blood tests to the symptomatic presentation and consultation(s) cannot be inferred from the NCDA data. Additional chronological details on test ordering and results, as captured in routinely collected electronic healthcare (EHC) records, could have allowed more informative interpretations. From EHC records, however, it is difficult to establish the first relevant consultation with symptoms of possible cancer (and therefore harder to establish the length of diagnostic intervals). Most presenting symptoms are also under-recorded in coded data. (15) In contrast in the NCDA, GPs could adjudicate the first relevant consultation from the patient records by accessing both structured and free-text information about presenting symptoms, thus allowing accurate estimates of diagnostic intervals.

Comparison with existing literature:

We expanded on previous relevant research (8) by assessing a much larger number of cancer sites and additional factors that influence blood test use; variation by blood test type, and the impact of investigations on the diagnostic interval.

A previously published study (n=100) found that over half of patients presenting in primary care with 'unexplained' complaints (fatigue, abdominal, and musculoskeletal complaints) were ordered blood tests. (16) We found similarly high proportions of patients presenting with non-alarm symptoms having blood tests (49%). The findings concord with data on primary care investigation use in the general population, where older age was associated with larger increase in test use over time. (7)

Common blood test use was associated with longer primary care and diagnostic intervals. This suggests that GPs must balance the diagnostic utility of common blood tests against likely delays in a subsequent referral, should such a referral be required. Prolonged DIs may encompass potentially avoidable diagnostic delays in cancer patients. (8,17) On the other hand, it is also possible that blood test use supports GP decisions when there is uncertainty about the underlying diagnosis; the counterfactual group in that respect is not patients in whom blood tests were not used, but patients (e.g. with non-specific symptoms) in whom the intervals to diagnosis may be even longer if no blood tests were to be used. Furthermore, while an alarm symptom may not justify a referral, abnormal blood test results may provide sufficient grounds for referral even if other eligibility criteria are not fulfilled in some patients. Therefore, in some patients longer intervals associated with blood test use may be deemed acceptable for supporting the diagnostic process. The association between test use and the length of the primary care, and even more so, the diagnostic intervals, appeared to be partially driven by cancer-site. These effects were nonetheless variable by symptom category. Differences in the length of the diagnostic intervals by blood test use chiefly relate to the post-primary care

management. It is impossible to infer whether the observed differences in intervals to diagnosis represents necessary or avoidable delays in our study, though this should be examined in further research.

Implications for Practice and Research:

Non-alarm symptoms have lower predictive value for cancer, likely prompting the observed greater use of blood tests in these patients. Further, patients with both alarm and non-alarm symptoms had the highest likelihood of blood testing, possibly reflecting greater degree of clinical uncertainty in these patients, or that alarm symptoms may have appeared subsequent to non-alarm symptoms. Nevertheless, half of patients presenting with non-alarm symptoms did not have a blood test. Although this cannot be directly inferred by our data, there may be greater potential for using common blood tests in these patients, particularly regarding possible referrals to rapid diagnostic centres. (6,18–20)

A quarter of patients who presented with alarm symptoms received a blood test prior to cancer diagnosis. These patients are eligible for fast-track specialist referral via the two-week-wait pathways, yet they experience longer intervals to diagnosis, associated with the use of a blood test. Blood test use in these patients may indicate diagnostic uncertainty or situations where GPs require further diagnostic support to aid their decision-making in patients not meeting all referral criteria (for example, in younger patients for those cancers with age criteria). More detailed evidence using qualitative methods would help contextualise what influences GPs decision-making to order blood tests in patients with alarm symptoms.

Blood test use may be enhanced through interventions aimed at addressing current logistical and practical barriers (rather than decision support interventions), such as simple modifications to the choice architecture on blood test ordering forms. (21,22)

Future research should explore variation in blood test use within specific populations of cancer patients and clinical scenarios, and incorporate qualitative methods to help understand likely drivers of use (or lack of use) of common blood tests in patients presenting to a GP with new symptoms.

In conclusion, common blood tests are frequently used in cancer patients before referral, but their use is variable. Our findings indicate potential unmet need for interventions to reduce the risk of underuse and overuse of blood tests within certain populations of cancer patients.

Acknowledgements:

The authors would like to thank all GPs and health professionals who participated in the NCDA, and contributing Cancer Research UK staff; the National Cancer Registration and Analysis Service, NHS England, the Royal College of General Practitioners, Macmillan Cancer Support, and Health Data Insight. This work uses data that has been provided by patients and collected by the NHS as part of their care and support. The data is collated, maintained and quality assured by the National Cancer Registration and Analysis Service, which is part of NHS Digital (although Public Health England (PHE) at the time of data collection). The NCDA received enabling support from Cancer Research UK, NHS England, and the National Cancer Registration and Analysis Service.

Contributors:

Ben Cranfield (BC): Conceptualisation, Methodology, Formal analysis, Writing - original draft. **Gary A. Abel (GAA):** Methodology, Writing - review & editing. **Ruth Swann (RS):** Writing – review & editing. **Sean Mcphail (SM):** Writing – review & editing. **Greg P. Rubin (GPR):** Writing - review & editing. **Georgios Lyratzopoulos (GL):** Methodology, Conceptualisation, Writing - review & editing, Supervision. **Minjoung Monica Koo (MMK):** Methodology, Conceptualisation, Writing - review & editing, Supervision.

Funding:

This research relates to Cancer Research UK project C18081/A29738 and the CanTest Collaborative, which is funded by Cancer Research UK [C8640/A23385], of which GPR is Chair, GL Associate Director, GAA Co-investigator, MMK Postdoctoral Fellow and BC Doctoral candidate. GL is supported by Cancer Research UK Clinician Advanced Scientist Fellowship [grant number: C18081/ A18180]. GA is supported by the National Institute for Health Research Applied Research Collaboration South West Peninsula. The views expressed are those of the authors and not necessarily those of Cancer Research UK.

Competing interests:

None declared

Ethical Approval:

Ethical approval was obtained by the London Hampstead Research Ethics Committee (REC reference: 20/EE/0103).

Data availability statement:

Data are available through the Office of Data Release of the National Disease Registration Service of NHS Digital.

References

1. Ahmad AS, Ormiston-Smith N, Sasieni PD. Trends in the lifetime risk of developing cancer in Great Britain: comparison of risk for those born from 1930 to 1960. *Br J Cancer* 2015; **112(5)**: 943-947
2. Public Health England. *Routes to Diagnosis: 2006 to 2017 results*. 2020. <https://www.gov.uk/government/statistics/routes-to-diagnosis-2006-to-2017-results/routes-to-diagnosis-2006-to-2017-results> [accessed 2021 Mar 18].
3. Koshiaris C, Van den Bruel A, Oke JL, et al. Early detection of multiple myeloma in primary care using blood tests: a case-control study in primary care. *Br J Gen Pract* 2018; **68(674)**: 586-593
4. Bailey SE, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. *Br J Gen Pract* 2017; **67(659)**: 405-413
5. Mounce LT, Hamilton W, Bailey SE. Cancer incidence following a high-normal platelet count: cohort study using electronic healthcare records from English primary care. *Br J Gen Pract* 2020; **70(698)**: 622–628.
6. Hopkins R, Bailey SE, Hamilton WT, Shephard EA. Microcytosis as a risk marker of cancer in primary care: a cohort study using electronic patient records. *Br J Gen Pract* 2020; **70(696)**: 457-462
7. O’Sullivan JW, Stevens S, Hobbs FDR, et al. Temporal trends in use of tests in UK primary care, 2000–15, retrospective analysis of 250 million tests. *BMJ*. 2018;**363**:k4666.
8. Rubin GP, Saunders CL, Abel GA, et al. Impact of investigations in general practice on timeliness of referral for patients subsequently diagnosed with cancer: analysis of national primary care audit data. *Br J Cancer* 2015; **112**: 676–687.
9. Lyratzopoulos G, Wardle J, Rubin G. Rethinking diagnostic delay in cancer: how difficult is the diagnosis? *BMJ* 2014; **349**: g7400.
10. Pearson C, Poirier V, Fitzgerald K, et al. Cross-sectional study using primary care and cancer registration data to investigate patients with cancer presenting with non-specific symptoms. *BMJ Open* 2020; **10(1)**:e033008
11. Zhou Y, Mendonca SC, Abel GA, et al. Variation in ‘fast-track’ referrals for suspected cancer by patient characteristic and cancer diagnosis: evidence from 670 000 patients with cancers of 35 different sites. *Br J Cancer* 2018; **118(1)**:24–31.

12. Swann R, McPhail S, Witt J, et al. Diagnosing cancer in primary care: results from the National Cancer Diagnosis Audit. *Br J Gen Pract* 2018; **68(666)**:e63–72.
13. Weller D, Vedsted P, Rubin G, et al. The Aarhus statement: improving design and reporting of studies on early cancer diagnosis. *Br J Cancer* 2012; **106**:1262–7.
14. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. NG12. 2015. <https://www.nice.org.uk/guidance/ng12> [Accessed 18 Feb 2019].
15. Price SJ, Stapley SA, Shephard E, et al. Is omission of free text records a possible source of data loss and bias in Clinical Practice Research Datalink studies? A case-control study. *BMJ Open* 2016; 6(5):e011664.
16. Koch H, van Bokhoven MA, ter Riet G, et al. What makes general practitioners order blood tests for patients with unexplained complaints? A cross-sectional study. *Eur J Gen Pract* 2009; **15(1)**: 22-8.
17. Swann R, Lyratzopoulos G, Rubin G, et al. The frequency, nature and impact of GP-assessed avoidable delays in a population-based cohort of cancer patients. *Cancer Epidemiol* 2020; **64**: 101617.
18. Chapman D, Poirier V, Vulkan D, et al. First results from five multidisciplinary diagnostic centre (MDC) projects for non-specific but concerning symptoms, possibly indicative of cancer. *Br J Cancer* 2020; **123(5)**:722–9.
19. Forster AS, Renzi C, Lyratzopoulos G. Diagnosing cancer in patients with ‘non-alarm’ symptoms: Learning from diagnostic care innovations in Denmark. *Cancer Epidemiol* 2018; **54**:101–3.
20. Watson J, Mounce L, Bailey SE, et al. Blood markers for cancer. *BMJ* 2019; **367**:l5774.
21. Litchfield I, Bentham L, Hill A, et al. Routine failures in the process for blood testing and the communication of results to patients in primary care in the UK: a qualitative exploration of patient and provider perspectives. *BMJ Qual Saf* 2015; **24(11)**: 681–90.
22. Shalev V, Chodick G, Heymann AD. Format change of a laboratory test order form affects physician behavior. *Int J Med Inform* 2009; **78(10)**:639–44.